Media
Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions – The Street
July 28, 2017 – Opiant Pharmaceuticals Inc. is best known today for its NARCAN® Nasal Spray used to treat opioid overdoses. But CEO Roger Crystal hopes to make overdoses a thing of the past for most addicts by developing a vaccine that can end heroin dependence.
NARCAN® Nasal Spray Creators Developing a ‘Heroin Vaccine’– Fox & Friends
July 27, 2017 – Opiant CEO Dr. Roger Crystal provides insight on ‘Fox & Friends’.
New Tool to Prevent Deaths from Opioid Overdoses – Fox Business Network’s “Mornings with Maria”
July 26, 2017 – Opiant CEO Dr. Roger Crystal on a new tool and efforts to battle the opioid crisis in America.
How a Nasal Spray can Save Lives from Opioid Overdoses – WTOP-DC Radio
July 15, 2017 – Phil Skolnick, Opiant’s Chief Scientific Officer, speaks with radio station WTOP-DC about Opiant’s intranasal naloxone.
NARCAN® Nasal Spray Inventor on U.S. Drug Epidemic – WSJ’s “Lunch Break”
September 15, 2016 – Opiant CEO Dr. Roger Crystal explains to The Wall Street Journal how NARCAN® Nasal Spray has been used to fight against opioid overdoses on the front line.
Opiant CEO Roger Crystal Shares Expertise on Treating Substance Abuse – NPR’s “BioTech Nation”
August 2, 2016 – With high-profile cases of opioid addiction in the headlines, Opiant Pharmaceuticals’ CEO, Dr. Roger Crystal, was a guest on NPR’s “BioTech Nation” program, hosted by Dr. Moira Gunn.